Skip to main content

Vitamin B12 (Cobalamin)

Vitamin B12 (cobalamin) is an essential water-soluble vitamin that serves as a cofactor for only two enzymes — cytosolic methionine synthase and mitochondrial methylmalonyl-CoA mutase — making it critical for DNA synthesis, one-carbon metabolism, erythropoiesis, and nervous-system myelination.[1][2][3] Deficiency affects approximately 2–3% of US adults, rising to 6% in those ≥ 60 years and 20% in those ≥ 85 years.[4]

B12 is absorbed in the terminal ileum via intrinsic-factor-mediated transport. This single anatomic fact makes B12 surveillance universal and lifelong in any reconstructive patient with ileal-conduit, orthotopic neobladder, augmentation cystoplasty, Indiana / Mainz pouch, ileal-ureter, or terminal-ileum resection for any reason — and symptoms can be delayed 3–5 years after the index operation because hepatic stores buffer the deficit. The dominant late morbidity is irreversible subacute combined degeneration of the spinal cord.

Biochemistry and Absorption​

Vitamin B12 refers to a family of cobalt-corrinoid compounds (cyanocobalamin, hydroxocobalamin, methylcobalamin, adenosylcobalamin) converted in vivo to two active coenzymes:[1][5]

  • Methylcobalamin (cytosol) — cofactor for methionine synthase, which remethylates homocysteine to methionine, maintaining S-adenosylmethionine (SAM), the universal methyl donor for DNA, RNA, histone methylation, and myelin synthesis.
  • Adenosylcobalamin (mitochondria) — cofactor for methylmalonyl-CoA mutase, converting L-methylmalonyl-CoA to succinyl-CoA for the TCA cycle.

Absorption is a multi-step process: gastric acid and pepsin release B12 from food proteins → binding to haptocorrin in saliva → pancreatic proteases degrade haptocorrin in the duodenum → B12 binds intrinsic factor (IF) → the IF-B12 complex is absorbed in the terminal ileum via the cubilin-amnionless receptor. Active absorption handles ~ 50% of usual dietary intake (4–6 μg/day) but is saturable. Passive absorption of pharmacologic doses (1,000+ μg) bypasses IF entirely at ~ 1% efficiency, which is the basis for high-dose oral therapy.[1][6]

Dietary Sources and Requirements​

Vitamin B12 is synthesized exclusively by bacteria and archaea; humans must obtain it from animal-source foods — meat, fish, shellfish, eggs, dairy — or from supplements / fortified foods.[6][3] The RDA for adults is 2.4 μg/day (pregnancy 2.6, lactation 2.8). No tolerable upper intake level has been established, as no adverse effects have been associated with excess B12 in healthy individuals.[7] Dairy-derived B12 may be more bioavailable than meat-derived B12 in older adults.[8]

Causes of Deficiency​

CategoryExamples
MalabsorptionPernicious anemia (autoimmune IF deficiency), atrophic gastritis, bariatric surgery, celiac disease, Crohn disease, ileal resection (incl. urologic reconstruction), pancreatic insufficiency
Dietary insufficiencyVegan diet (52% deficient), vegetarian diet (7% deficient), food insecurity, alcohol use disorder
MedicationsMetformin (NNH = 14), proton pump inhibitors (OR 1.42), H2 blockers (OR 1.25), nitrous oxide, colchicine
DemographicOlder age (reduced gastric acid), pregnancy (20–30% worldwide)

Pernicious anemia remains the most common cause of severe B12 deficiency. Metformin inhibits calcium-dependent binding of the IF-B12 complex at the terminal ileum; a secondary analysis of a multicenter RCT found low / borderline B12 in 19.1% of the metformin group vs 9.5% of placebo.[4][9]

Clinical Manifestations​

Hematologic — Megaloblastic anemia with macrocytosis, hypersegmented neutrophils, pancytopenia. Severe cases can mimic thrombotic microangiopathy with hemolytic anemia, thrombocytopenia, elevated LDH, low haptoglobin.[10][4] Importantly, macrocytosis is present in only ~ 24% of cases, and neurologic symptoms may precede or occur without any hematologic abnormalities.[4][11]

Neurologic — Subacute combined degeneration (demyelination of posterior and lateral columns) is the archetypal manifestation: impaired vibratory / proprioceptive sensation, spasticity, weakness, extensor plantar responses.[9][10] Peripheral neuropathy occurs in ~ 25% of deficient patients and may unusually begin in the hands or simultaneously in upper and lower limbs.[9] Autonomic dysfunction, optic neuropathy, and small-fiber neuropathy have also been described.[9]

Neuropsychiatric — Memory loss, cognitive impairment (OR 2.3 in those > 75 years), depression, psychosis ("megaloblastic madness"), personality changes. Reversible if treated early but can become permanent.[4][12]

Notably, the severity of megaloblastic anemia is inversely correlated with the degree of neurologic dysfunction — patients with the most severe myelopathy often have minimal anemia.[10]

Diagnosis​

A stepwise approach is recommended:[4][10][9]

  1. Total serum B12 — Initial test. Levels < 200 pg/mL are deficient; 200–350 pg/mL borderline; > 350 pg/mL generally normal.[4]
  2. Methylmalonic acid (MMA) — The key confirmatory test for borderline levels. Elevated MMA is reasonably specific for B12 deficiency (always decreases with B12 therapy). Nearly all patients with megaloblastic anemia or myelopathy have MMA > 500 nmol/L; 86% have levels > 1,000 nmol/L. Modest elevations (300–700 nmol/L) can occur with renal failure.[10]
  3. Total homocysteine — More sensitive but less specific than MMA, as it is also elevated in folate deficiency, homocystinuria, and renal failure.[10][9]
  4. Holotranscobalamin (holoTC) — A more sensitive and specific marker of B12 status (represents the metabolically active fraction delivered to tissues), but availability is limited and cost is higher.[9][4]

Both MMA and homocysteine are elevated in > 98% of patients with clinical B12 deficiency, including those with isolated neurologic manifestations.[10] Up to 50% of patients with low serum B12 who have normal MMA and homocysteine do not respond to replacement therapy, indicating false-positive low B12 results.[10]

Etiologic Workup​

Patients without a clear cause should be tested for atrophic gastritis (H. pylori, anti-intrinsic-factor antibodies, anti-parietal-cell antibodies).[4] In patients with IBD, the AGA recommends yearly screening in those with extensive ileal disease or terminal-ileal resection > 30 cm.[13]

Treatment​

Oral vs IM supplementation — A 2018 Cochrane review found no significant difference in B12 normalization between oral (1,000 μg/day) and IM, even in pernicious anemia.[14][4] Oral B12 at 2,000 μg/day may achieve higher serum levels than IM.[14] A 2024 prospective cohort confirmed that oral cyanocobalamin 1,000 μg/day corrected deficiency in 88.5% of pernicious anemia patients within 1 month, with sustained normalization at 12 months.[15]

Recommended regimens:

  • Oral — 1,000–2,000 μg daily cyanocobalamin; efficacious, cost-effective, appropriate for most patients.[4][16]
  • IM / SC — 1 mg weekly × 4 weeks, then 1 mg monthly; preferred for severe deficiency, neurologic manifestations, or when rapid repletion is needed.[16][17]
  • IBD with ileal disease — IM / SC 1,000 μg at 1–4 week intervals for life is preferred over oral / sublingual.[13]
  • Post-bariatric surgery — Baseline and annual B12; more frequent monitoring (every 3 months) in the first postoperative year.[18]

Cyanocobalamin is the most studied and widely used oral form. Methylcobalamin and hydroxocobalamin are alternatives; evidence for superiority is lacking.[17][19]

Elevated Vitamin B12 — A Warning Sign​

Persistently elevated B12 (> 1,000 pg/mL on two measurements) is an underrecognized finding affecting > 8% of tested patients and is associated with serious underlying disease:[4][20]

  • Solid cancers — HR 5.9 for incident solid cancer (liver, kidney, lung, breast, GI); risk highest in the first year after measurement.[20][21]
  • Hematologic malignancies — CML, polycythemia vera, myeloproliferative neoplasms.[4][22]
  • Liver disease — Hepatocellular damage releases intracellular B12; seen in hepatitis, cirrhosis, HCC.[22][23]
  • All-cause mortality — A dose-response meta-analysis of 22 cohort studies (92,346 individuals) found each 100 pmol/L increase in serum B12 was associated with a 4% higher risk of all-cause mortality in the general population and 6% in older adults.[24]

Exogenous supplementation should first be excluded. If B12 is persistently elevated, a reasonable workup is CBC, CMP, liver ultrasound, and confirmation that age-appropriate cancer screening is current.[4][25]

Reconstructive Relevance​

The Defining Reconstructive Scenario: Ileal Bowel Reconstruction​

Any reconstruction that uses, bypasses, or removes terminal ileum disables IF-mediated B12 absorption and creates lifelong deficiency risk:

  • Ileal conduit (Bricker) — ~ 15–20 cm ileum reservoir; B12 deficiency develops over years.
  • Orthotopic ileal neobladder (Studer, Hautmann) — 40–60 cm ileum reservoir; highest cumulative deficiency risk.
  • Augmentation ileocystoplasty — 20–25 cm ileum patch; deficiency in roughly 20% by 5 years.
  • Indiana pouch / Mainz pouch — terminal-ileum + cecum reservoirs; long-term deficiency expected.
  • Ileal-ureter substitution — generally smaller bowel segment, lower cumulative risk but still surveillance-relevant.

Hepatic B12 stores buffer 3–5 years of zero intake, which is why symptoms typically emerge years (sometimes a decade) after the index operation. The classic patient is the long-term cystectomy survivor who presents with progressive paresthesias, gait instability, or cognitive change. The clinical sin is failing to consider B12 in a patient with prior ileal-bowel reconstruction, regardless of how distant.

Surveillance Schedule (Reconstructive)​

  • Baseline at the time of any ileal-bowel reconstruction.
  • Annually thereafter, indefinitely (AUA / SUFU urinary-diversion surveillance bundle).
  • Symptom-driven anytime: new paresthesias, gait change, cognitive change, macrocytosis on routine CBC.
  • Replace with IM cyanocobalamin / hydroxocobalamin 1 mg monthly when deficiency is confirmed; oral 1,000–2,000 μg daily is an evidence-based alternative for cooperative patients with adequate gastric / proximal-intestinal function (note: oral relies on passive absorption — adequate in most post-ileal-resection patients because pharmacologic doses bypass IF).
  • Cross-reference: Renal Function & Metabolic Surveillance for the canonical post-diversion bundle.

Other High-Yield Reconstructive Scenarios​

  • Post-bariatric reconstruction (especially RYGB and BPD-DS) — duodenal bypass impairs IF binding; baseline + annual B12 with q3-month monitoring in the first year.
  • Long-term metformin users undergoing reconstruction — NNH = 14; common in the diabetic urology population.
  • Long-term PPI users undergoing reconstruction — OR 1.42; reflux-medicated patients are frequently overlooked.
  • GLP-1 RA users — reduced dietary intake adds an absorption-independent mechanism.
  • Vegan / vegetarian gender-affirming and transitional-care patients — supplementation status should be confirmed before any major reconstruction.
  • Copper-mimic trap — In a patient with myeloneuropathy and a low-normal B12, consider copper deficiency (also causes subacute combined degeneration). See Copper — particularly relevant in post-bariatric and zinc-supplementing patients.

See Also​

References​

1. Mathew AR, Selita E, Regano C, et al. "Vitamin B12 and Reproductive Health: Clinical Insights, Emerging Mechanistic Understanding, and Nutritional Aspects." Molecular Reproduction and Development. 2026;93(2):e70088. doi:10.1002/mrd.70088

2. Calderón-Ospina CA, Nava-Mesa MO. "B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin." CNS Neuroscience & Therapeutics. 2020;26(1):5–13. doi:10.1111/cns.13207

3. Moravcová M, Siatka T, Krčmová LK, Matoušová K, Mladěnka P. "Biological Properties of Vitamin B12." Nutrition Research Reviews. 2025;38(1):338–370. doi:10.1017/S0954422424000210

4. Patel H, McGuirk R. "Vitamin B12 Deficiency: Common Questions and Answers." American Family Physician. 2025;112(3):294–300.

5. Coelho D, Suormala T, Stucki M, et al. "Gene Identification for the cblD Defect of Vitamin B12 Metabolism." The New England Journal of Medicine. 2008;358(14):1454–1464. doi:10.1056/NEJMoa072200

6. Allen LH. "Micronutrients — Assessment, Requirements, Deficiencies, and Interventions." The New England Journal of Medicine. 2025;392(10):1006–1016. doi:10.1056/NEJMra2314150

7. Sley EG, Fothergill A, Steel LB, et al. "Vitamin B12 Supplementation for Anaemia, Vitamin B12 Status, and Health Outcomes in Women of Reproductive Age." Cochrane Database of Systematic Reviews. 2026;5:CD016233. doi:10.1002/14651858.CD016233

8. Huang HH, Cohen AA, Gaudreau P, et al. "Vitamin B-12 Intake From Dairy but Not Meat Is Associated With Decreased Risk of Low Vitamin B-12 Status and Deficiency in Older Adults From Quebec, Canada." The Journal of Nutrition. 2022;152(11):2483–2492. doi:10.1093/jn/nxac143

9. Gwathmey KG, Grogan J. "Nutritional neuropathies." Muscle & Nerve. 2020;62(1):13–29. doi:10.1002/mus.26783

10. Stabler SP. "Vitamin B12 Deficiency." The New England Journal of Medicine. 2013;368(2):149–160. doi:10.1056/NEJMcp1113996

11. Reynolds E. "Vitamin B12, Folic Acid, and the Nervous System." The Lancet Neurology. 2006;5(11):949–960. doi:10.1016/S1474-4422(06)70598-1

12. Toh BH, van Driel IR, Gleeson PA. "Pernicious Anemia." The New England Journal of Medicine. 1997;337(20):1441–1448. doi:10.1056/NEJM199711133372007

13. Hashash JG, Elkins J, Lewis JD, Binion DG. "AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review." Gastroenterology. 2024;166(3):521–532. doi:10.1053/j.gastro.2023.11.303

14. Wang H, Li L, Qin LL, et al. "Oral Vitamin B12 Versus Intramuscular Vitamin B12 for Vitamin B12 Deficiency." Cochrane Database of Systematic Reviews. 2018;3:CD004655. doi:10.1002/14651858.CD004655.pub3

15. Lacombe V, Vinatier E, Roquin G, et al. "Oral Vitamin B12 Supplementation in Pernicious Anemia: A Prospective Cohort Study." The American Journal of Clinical Nutrition. 2024;120(1):217–224. doi:10.1016/j.ajcnut.2024.05.019

16. Mauermann ML, Staff NP. "Peripheral Neuropathy." JAMA. 2026;335(3):255–266. doi:10.1001/jama.2025.19400

17. Wolffenbuttel BHR, McCaddon A, Ahmadi KR, Green R. "A Brief Overview of the Diagnosis and Treatment of Cobalamin (B12) Deficiency." Food and Nutrition Bulletin. 2024;45(1_suppl):S40–S49. doi:10.1177/03795721241229500

18. Mechanick JI, Apovian C, Brethauer S, et al. "Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures — 2019 Update." Obesity. 2020;28(4):O1–O58. doi:10.1002/oby.22719

19. Obeid R, Andrès E, Češka R, et al. "Diagnosis, Treatment and Long-Term Management of Vitamin B12 Deficiency in Adults: A Delphi Expert Consensus." Journal of Clinical Medicine. 2024;13(8):2176. doi:10.3390/jcm13082176

20. Lacombe V, Chabrun F, Lacout C, et al. "Persistent Elevation of Plasma Vitamin B12 Is Strongly Associated With Solid Cancer." Scientific Reports. 2021;11(1):13361. doi:10.1038/s41598-021-92945-y

21. Arendt JFH, Sørensen HT, Horsfall LJ, Petersen I. "Elevated Vitamin B12 Levels and Cancer Risk in UK Primary Care: A THIN Database Cohort Study." Cancer Epidemiology, Biomarkers & Prevention. 2019;28(4):814–821. doi:10.1158/1055-9965.EPI-17-1136

22. Ermens AA, Vlasveld LT, Lindemans J. "Significance of Elevated Cobalamin (Vitamin B12) Levels in Blood." Clinical Biochemistry. 2003;36(8):585–590. doi:10.1016/j.clinbiochem.2003.08.004

23. Arendt JF, Nexo E. "Cobalamin Related Parameters and Disease Patterns in Patients With Increased Serum Cobalamin Levels." PLoS One. 2012;7(9):e45979. doi:10.1371/journal.pone.0045979

24. Liu K, Yang Z, Lu X, et al. "The Origin of Vitamin B12 Levels and Risk of All-Cause, Cardiovascular and Cancer Specific Mortality: A Systematic Review and Dose-Response Meta-Analysis." Archives of Gerontology and Geriatrics. 2024;117:105230. doi:10.1016/j.archger.2023.105230

25. Arendt JF, Nexo E. "Unexpected High Plasma Cobalamin: Proposal for a Diagnostic Strategy." Clinical Chemistry and Laboratory Medicine. 2013;51(3):489–496. doi:10.1515/cclm-2012-0545